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Introduction: Preeclampsia (PE) is a life-threatening pregnancy disorder characterized by wide-spread
endothelial dysfunction. Placental factors circulating in the maternal blood are believed to cause
endothelial dysfunction. Our previous study identiﬁed HtrA4 as a placenta-speciﬁc serine protease that is
released into the maternal circulation and signiﬁcantly increased in early-onset PE. In this study, we
examined the impact of HtrA4 on expression of endothelial genes related to vessel biology, using human
umbilical vein endothelial cells (HUVECs) as a model.
Methods: HUVECs were treated with 0 or 3 mg/ml HtrA4 (highest concentration seen in PE circulation)
for 24 h and analysed by an endothelial cell biology PCR array containing 84 genes. HtrA4-induced
changes were then validated by real-time RT-PCR and ELISA for time and dose dependency.
Results: High levels of HtrA4 signiﬁcantly altered the expression of a range of genes related to inﬂam-
mation, vaso-activity, angiogenesis, cell adhesion, platelet activation and coagulation. In particular, pro-
inﬂammatory genes IL6, PTGS2 (COX2) and IL1B were signiﬁcantly increased by HtrA4. IL6 protein in
HUVEC media was also drastically increased. THBD, an anticoagulant factor reported to be increased in
PE, was signiﬁcantly up-regulated by HtrA4. In contrast, THBS1, which is involved in many regulatory
processes of endothelial cell biology, was severely down-regulated by HtrA4.
Discussion: HtrA4 signiﬁcantly increased the inﬂammatory responses of HUVECs, and altered their
expression of a number of genes important for vessel biology. These data suggest that placenta-derived
HtrA4 that is increased in PE circulation is a potential causal factor of endothelial dysfunction.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Preeclampsia (PE) is a life-threatening disorder of human
pregnancy affecting 2e8% of pregnancies worldwide [1,2]. PE can
progress rapidly leading to multi-organ failure and symptoms are
closely linked to wide-spread endothelial dysfunction [3]. It is well
accepted that in PE, the placenta releases abnormal amounts/types
of factors into the maternal circulation and these circulating factors
contribute to endothelial dysfunction and the maternal syndrome
of PE [4]. Signiﬁcantly elevated circulating factors in PE includeical Research, 27-31 Wright
).
r Ltd. This is an open access articlecytokines, antiangiogenic factors, syncytiotrophoblast microparti-
cles and activated leukocytes [5e8]. Changes in many of these
factors are believed to reﬂect an exacerbated maternal response to
pregnancy, which itself is considered as a low grade systemic
inﬂammation [9]. One study has shown that serum from pre-
eclamptic women is cytotoxic to endothelial cells in vitro, and that
clinical condition improves drastically after 24e48 h postpartum
when the cytotoxic activity is dramatically reduced [10].
Endothelial injury in PE is evidenced by the appearance of
morphological lesions, glomerular endotheliosis, and increased
circulating levels of ﬁbronectin, von Willebrand factor and cyto-
kines, all of which can be secreted by endothelial cells as an in-
ﬂammatory reaction [11,12]. Endothelial cells can also alter their
synthesis of vaso-relaxing/vasoconstrictors and pro/anticoagulantsunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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vasculature can persist many years after PE. A study revealed
vascular endothelial defects in women even three years after a PE
pregnancy, and the data suggested that the impairment was more
severe with recurrent PE [13]. PE-induced endothelial injury has
long-term and harmful consequences, for instance, women who
had PE have a higher risk of developing cardiovascular diseases
many years postpartum [14].
PE can be classiﬁed into two distinct subtypes, early-onset
which occurs before 34 weeks of gestation, and late-onset PE
which occurs after 34 weeks [15]. Emerging evidence strongly
suggests that the two PE subtypes have vastly different etiologies,
and early-onset PE poses a far more signiﬁcant maternal risk, with a
20-fold highermortality rate than late-onset PE [16e19]. The risk of
cardiovascular disease is also much higher inwomenwho have had
early-onset than late-onset PE [20e22], suggesting that endothelial
injury is more profound in early-onset than late-onset PE.
We have recently reported that high temperature requirement
A4 (HtrA4) is a placenta-speciﬁc protease that is signiﬁcantly
increased in the circulation of early-onset PE [23]. HtrA4 belongs to
a serine protease family that also includes HtrA1, HtrA2 and HtrA3.
These proteins are known to function as ATP-independent protein
quality control factors to regulate cellular processes such as pro-
liferation, unfolded stress response, programmed cell death and
aging [24]. All HtrAs contain a trypsin-like serine protease domain
and are proven to have catalytic activities [25]. HtrA1, HtrA3 and
HtrA4 share a similar domain structure and are secreted out of cells,
whereas HtrA2 has a transmembrane domain and is localized in
mitochondria [26]. HtrA4 is the newest member of the mammalian
HtrA family, it is expressed only by the placenta and secreted into
the maternal circulation [23]. In a normal pregnancy, HtrA4 serum
levels increase progressively to around 24e25 weeks of gestation,
then remain stable throughout the remainder of the pregnancy
[23].
Our study showed that in early-onset PE, both the placental
production and circulating levels of HtrA4 are signiﬁcantly
increased [23]. We further demonstrated that HtrA4 at high con-
centrations seen in early-onset PE disrupted the tube formation of
human umbilical vein endothelial cell (HUVEC), disturbed cellular
integrity and increased cellular permeability [23]. These results
suggest high levels of circulating HtrA4 of placental origin may
contribute to endothelial dysfunction and the development of
early-onset PE.
In this study, using HUVEC as a model, we ﬁrst examined the
impact of HtrA4 on expression of endothelial genes involved in
vessel cell biology by an array approach, then validated the data by
real-time RT-PCR and ELISA.
2. Materials and methods
2.1. Cell culture
HUVECs (ATCC, Maryland, USA) were cultured at 37 C in a
humidiﬁed atmosphere of 5% CO2 in air, and maintained in DMEM
(Thermo Fisher Scientiﬁc, VIC, Australia) supplemented with 1%
antibiotics (Thermo Fisher Scientiﬁc), 2 mM L-glutamine (Sigma-
Aldrich, Missouri, USA), 1 mM sodium pyruvate (Thermo Fisher
Scientiﬁc) and 10% fetal bovine serum (Thermo Fisher Scientiﬁc).
The starting passage of the HUVECs was 13, and the experiments
were completed within eight passages. The cells were cultured in
12-well plates (Thermo Fisher Scientiﬁc) at 1 105 per well density
for 24 h (h), then treated with recombinant HtrA4 (BioTeZ, Berlin,
Germany, 1.5 mg/ml or 3.0 mg/ml) or vehicle control for 24 or 48 h.
The vehicle control contains 150 mM NaCl, 5 mM CaCl2, 50 mM
Tris-HCl pH 7.5, 0.05% Brij 35 solution, 50 mM imidazole inultrapure H2O. The two doses of HtrA4 were chosen to represent
the median and highest levels of HtrA4 found in early-onset PE
circulation [23]. After the treatment, media were collected and cells
were used for RNA extraction. The experiment was repeated four
times.
2.2. RNA extraction
RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden,
Germany) and contaminating DNA was removed using RNase-free
DNase (Qiagen) according to the manufacturers' protocols. The
RNA concentration was determined using Nanodrop ND-1000
(Thermo Fisher Scientiﬁc).
2.3. PCR array for endothelial cell biology
RNA samples from vehicle control or 3 mg/ml HtrA4 treatment
for 24 h were pooled from three independent experiments, and
500 ng of the pooled RNA presenting control and HtrA4 treatment
(3 mg/ml, 24 h) was reverse transcribed into complementary DNA
(cDNA) using RT2 First Strand Kit (Qiagen). A RT2 Proﬁler 84 gene
PCR array (Qiagen) was screened as per manufacturer's instruction
on an ABI 7900 HT Fast real-time machine (Applied Biosystems,
VIC, Australia). The results were analysed using Qiagen RT2 proﬁler
PCR array data analysis software.
2.4. Real-time RT-PCR analysis
Genes showing more than 2-fold differences in expression on
the array between the vehicle control and HtrA4 treatment were
validated by real-time RT-PCR. RNA (300 ng) from three indepen-
dent experiments of 24 h and 48 h treatment with 0, 1.5 mg/ml and
3.0 mg/ml HtrA4 was reverse transcribed in 20 ml using SuperScript
III First-Strand kit (Invitrogen, VIC, Australia) as per manufacturer's
protocol. Real-time RT-PCR was performed with primers speciﬁed
in Supplementary Table 1 on an ABI 7900 HT Fast real-time ma-
chine with the following conditions: 1) 95 C for 10 min for enzyme
activation, 2) 40 cycles of denaturation (15 s at 95 C), annealing (5 s
at 58 C), extension (10 s at 72 C), and a single ﬂuorescence
measurement at 70e75 C for quantitation, and 3) dissociation
curve assessment between 60 C and 95 C with continuous ﬂuo-
rescence measurement. All cDNA samples were diluted 1:80, and
PCR reaction was prepared to a ﬁnal volume of 10 ml with 5 ml SYBR
Green PCR Master Mix (Applied Biosystems), 4 ml diluted cDNA
sample and 0.5 mM ﬁnal concentration of forward and reverse
primers. All samples were run in triplicates, each gene expression
were normalised to 18 S, and fold changes were calculated using
DDCt.
2.5. Enzyme-linked immunosorbent assay (ELISA)
The secreted levels of interleukin (IL)6 and monocyte chemo-
attractant protein (MCP)1 in the above treated cell media were
measured by ELISA (Ray Biotech, Georgia, USA) according to man-
ufacturer's instruction.
2.6. Cytokine antibody array
A cytokine antibody array for 36 cytokines (R&D System, Min-
nesota, USA) was analysed to determinewhether HtrA4 alters these
cytokines in HUVECs. Conditioned media from cells treated with
vehicle control or 3.0 mg/ml HtrA4 for 24 h from four independent
experiments were pooled for the array analysis. Dots representing
36 cytokines were analysed by densitometry using ImageJ software
(National Institutes of Health, USA).
Fig. 1. HtrA4-induced changes in mRNA expression of genes involved in inﬂammatory responses. A) PCR array data. RNA samples from vehicle control (vc) or 3 mg/ml HtrA4
treatment for 24 h were pooled from 3 experiments for the array. Data is expressed as HtrA4-induced fold changes relative to the control. Genes that showed >2-fold differences (in
black bar) were chosen for validation by real-time RT-PCR. (BeF) Real-time RT-PCR analysis of CCL2 (B), ALOX5 (C), PTGS2 (D), IL6 (E) and IL1B (F). Cells were treated with 0, 1.5 mg/ml
or 3 mg/ml HtrA4 for 0, 24 or 48 h, n ¼ 3. Data is expressed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Fig. 2. HtrA4-induced changes in mRNA expression of genes involved in vaso-activities and angiogenesis. A) PCR array data. RNA samples from vehicle control (vc) or 3 mg/ml HtrA4
treatment for 24 h were pooled from 3 experiments for the array. Data is expressed as HtrA4-induced fold changes relative to the control. Genes showed >2-fold differences in
mRNA (in black bar) were chosen for validation by real-time RT-PCR. (BeE) Real-time RT-PCR analysis of EDN1 (B), PTGIS (C), FGF2 (D) and VEGFA (E). Cells were treated with 0,
1.5 mg/ml or 3 mg/ml HtrA4 for 0, 24 or 48 h, n ¼ 3. Data is expressed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Statistical analyses were conducted using GraphPad Prism (v.6,
GraphPad Software Inc., CA). Data are expressed as mean ± SD,
comparison was made using two-way ANOVA followed by Tukey's
post-hoc tests, and differencewas considered signiﬁcant if p < 0.05.3. Results
We used HUVECs as a model and examined the effect of HtrA4
on the expression of 84 genes that are involved in endothelial cell
biology (Supplementary Table 2). These genes were broadly cat-
egorised into four groups: inﬂammation, angiogenesis and vaso-
activities, platelet activation and cell adhesion, coagulation and
apoptosis. Total RNA from cells treated with vehicle control or 3 mg/
ml HtrA4 (highest level detected in early-onset PE serum) for 24 h
Fig. 3. HtrA4-induced changes in mRNA expression of genes involved in cell adhesion and platelet activation. A) PCR array data. RNA samples from vehicle control (vc) or 3 mg/ml
HtrA4 treatment for 24 h were pooled from 3 experiments for the array. Data is expressed as HtrA4-induced fold changes relative to the control. Genes showed >2-fold differences
in mRNA (in black bar) were chosen for validation by real-time RT-PCR. (BeD) Real-time RT-PCR analysis of THBS1 (B), SERPINE1 (C) and IL11 (D). Cells were treated with 0, 1.5 mg/ml
or 3 mg/ml HtrA4 for 0, 24 or 48 h, n ¼ 3. Data is expressed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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changes in expression were then validated by real-time RT-PCR
for time and dose dependency, using cells treated with vehicle
control, 1.5 mg/ml or 3 mg/ml HtrA4 for 0, 24 or 48 h. The array data
are presented together with the real-time RT-PCR validation for
each of the four gene groups categorised above.3.1. HtrA4 regulation of genes involved in endothelial inﬂammation
Among the ten genes related to inﬂammation, ﬁve were altered
by HtrA4 by more than 2 folds on the PCR array, two down-
regulated and three up-regulated (Fig. 1A). These ﬁve genes were
further examined by real-time RT-PCR for time and HtrA4 dose
dependency. For the two down-regulated genes, CCL2 (also known
as MCP1) and ALOX5, CCL2 mRNA was signiﬁcantly reduced by
Fig. 4. HtrA4-induced changes in mRNA expression of genes involved in apoptosis and coagulation. A) PCR array data. RNA samples from vehicle control (vc) or 3 mg/ml HtrA4
treatment for 24 h were pooled from 3 experiments for the array. Data is expressed as HtrA4-induced fold changes relative to the control. Genes showed >2-fold differences in
mRNA (in black bar) were chose for validation by real-time RT-PCR. (BeE) Real-time RT-PCR analysis of BCL2 (B), OCLN (C),MMP1 (D) and THBD (E). Cells were treated with 0, 1.5 mg/
ml or 3 mg/ml HtrA4 for 0, 24 or 48 h, n ¼ 3. Data is expressed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Data shown as mean ± SD.
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more profound at 48 h than 24 h (Fig. 1B). Although ALOX5 showed
a 2.9-fold reduction on the array, real-time RT-PCR did not ﬁnd
signiﬁcant changes in ALOX5mRNA across all treatment conditions
(Fig. 1C). This is likely due to the low expression of ALOX5 in
HUVECs. For the three up-regulated genes (Fig. 1A), PTGS2 (also
called COX2), IL6 and IL1B were all validated by real-time RT-PCR.
PTGS2 mRNA was signiﬁcantly up-regulated by 3 mg/ml HtrA4 at
48 h time point (Fig. 1D). IL6 mRNA was signiﬁcantly increased by
3 mg/ml HtrA4 at the longer time point (Fig. 1E). In contrast, IL1B
expression was increased by HtrA4 dose- and time-dependently
(Fig. 1F).3.2. HtrA4 regulation of genes associated with angiogenesis and
vaso-activities
Thirty-one genes on the array were categorised into this group
(Fig. 2A). The PCR array analysis identiﬁed two down-regulated
(EDN1 and PTGIS) and two up-regulated (FGF2 and VEGFA) genes
(Fig. 2A). Real-time RT-PCR conﬁrmed that EDN1 was signiﬁcantly
down-regulated by HtrA4 in a dose- and time-dependent manner
(Fig. 2B), but PTGIS mRNA was not altered by HtrA4 (Fig. 2C). The
two up-regulated genes, FGF2 and VEGFA, were conﬁrmed by real-
time PCR to be signiﬁcantly increased by HtrA4 (Fig. 2DeE). The up-
regulation was greatest at 48 h with 3 mg/ml HtrA4 treatment
(Fig. 2DeE).
Table 1
List of genes that were validated by real-time RT-PCR to be signiﬁcantly affected by HtrA4.
Gene category Gene
name
Regulation by
HtrA4
Functions in endothelial cells
Inﬂammatory Response CCL2/
MCP1
Involved in immnoregulatory and inﬂammatory processes, recruitment of monocytes and macrophages
PTGS2/
COX2
A key enzyme in prostaglandin biosynthesis, and is involved in inﬂammation and mitogenesis
IL6 Major functions in inﬂammation and the maturation of B cells, highly up-regulated in PE circulation
IL1B Mediates inﬂammatory response and various cellular activities, including proliferation and differentiation
Angiogenesis and Vaso-
activities
EDN1/
ET1
A secreted peptide that acts as a vasoconstrictor
FGF2 Involves in ranges of biological processes, including mitogenic and angiogenic activities
VEGFA Acts speciﬁcally on endothelial cells and has various functions, including angiogenesis and cell growth
Platelet Activation and Cell
Adhesion
THBS1 Mediates cell-to-cell and cell-to-matrix interactions and plays a role in platelet aggregation and angiogenesis
SERPINE1 A major inhibitor of tissue plasminogen activator and urokinase, acts on blood vessels to inhibit ﬁbrinolysis
IL11 Stimulates the proliferation of hematopoietic cells and megakaryocyte to increase platelet production
Coagulation and Apoptosis OCLN An integral membrane protein that is required for cytokine-induced regulation of the tight junction
MMP1 Involves in the breakdown of extracellular matrix in many physiological processes
THBD An endothelial-speciﬁc receptor that binds to thrombin to activate protein C, which degrades clotting factors. It is a
marker for endothelial dysfunction
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Twenty-two genes on the array were in this category (Fig. 3A).
The PCR array identiﬁed one down-regulated (THBS1) and two up-
regulated (SERPINE1 and IL11) genes (Fig. 3A). THBS1 is responsible
for cell adhesion, whereas SERPINE1 and IL11 are involved in
platelet activation. Real-time RT-PCR conﬁrmed that THBS1 mRNA
was signiﬁcantly down-regulated by HtrA4 in a dose- and time-
dependent manner (Fig. 3B). Both SERPINE1 and IL11 were also
validated by rea-time RT-PCR to be signiﬁcantly up-regulated by
HtrA4 dose- and time-dependently (Fig. 3CeD).3.4. HtrA4 regulation of genes involved in apoptosis and
coagulation
There were twenty-two genes in this group (Fig. 4A). The PCR
array identiﬁed one down-regulated (BCL2) and three up-regulated
(OCLN,MMP1 and THBD) genes (Fig. 4A). BCL2, which is essential for
apoptosis, showed no HtrA4-induced changes in mRNA expression
by real-time RT-PCR (Fig. 4B). For the three up-regulated genes,
OCLN, encoding a cell-junction protein, was conﬁrmed by real-time
RT-PCR to be up-regulated by HtrA4, and most prominently at 48 h
(Fig. 4C). For the two up-regulated genes that are involved in
coagulation, MMP1 mRNA was signiﬁcantly increased by 3 mg/ml
HtrA4 at 48 h (Fig. 4D). In contrast, THBD mRNA was signiﬁcantly
increased by HtrA4 in a dose- and time-dependent manner
(Fig. 4E).
In total, thirteen genes were conﬁrmed by real-time RT-PCR to
be signiﬁcantly altered by HtrA4, ten were up-regulated and three
down-regulated (Table 1). Functions of these thirteen genes and
their potential relevance to endothelial dysfunction and PE are alsosummarised in Table 1.3.5. Validation of HtrA4 regulation of pro-inﬂammatory factors at
the protein level
As heightened inﬂammation is a key feature of endothelial
dysfunction and PE, we selected two genes from the inﬂammation
group, one up-regulated (IL6, Fig. 1F) and one down-regulated
(CCL2, Fig. 1B) for validation at the protein level to further
conﬁrm the real-time RT-PCR data. The levels of these two cyto-
kines in HUVEC media were measured by ELISA. IL6 protein was
signiﬁcantly increased by 3 mg/ml HtrA4 at 48 h time points, the
lower dose of HtrA4 (1.5 mg/ml) and the shorter time point (24 h)
had no signiﬁcant effect on IL6 protein (Fig. 5A). This is highly
consistent with the real-time RT-PCR data (Fig. 1E). On the other
end of the spectrum, the only down-regulated inﬂammatory gene,
CCL2, which encodes MCP1, was signiﬁcantly reduced at the protein
level by HtrA4 in a dose- and time-dependent manner (Fig. 5B), and
the pattern is identical to its mRNA changes (Fig. 1B).
As both IL6 and MCP1 are cytokines and only a few cytokines
were on the PCR array, we further examined whether HtrA4 affects
a broad range of cytokines using an antibody array for 36 cytokines
(Fig. 5C). HUVEC media treated with either vehicle control or 3 mg/
ml HtrA4 for 24 h were pooled from four independent experiments
and applied onto the cytokine array. Of the thirty-six cytokines
examined, IL6 showed a 4.6-fold increase andMCP1 displayed a 11-
fold reduction by HtrA4 compared to vehicle control (Fig. 5C), the
other thirty-four cytokines examined showed no signiﬁcant dif-
ference between vehicle control and HtrA4 treatment (Fig. 5C).
These data further conﬁrmed the speciﬁc and opposing effect of
HtrA4 on IL6 and MCP1.
Fig. 5. HtrA4-induced changes in cytokines at the protein level. A-B) ELISA detection of IL6 (A) and MCP1 (B) in media of HUVECs following treatment with 0, 1.5 mg/ml or 3 mg/ml
HtrA4 for 24 or 48 h, n ¼ 4. Data is expressed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. C) Analysis of 36 cytokines by an antibody array. Media from HUVECs treated with
vehicle control (vc) or 3 mg/ml HtrA4 for 24 h were pooled from 4 independent experiments and analysed on the array. The graph shows densitometric reading of each cytokine.
Signiﬁcant changes were detected only for IL6 and MCP1, consistent with the ELISA data shown in (AeB).
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This study demonstrated that HtrA4 signiﬁcantly affected
endothelial cell gene expression. At a concentration found in early-
onset PE circulation, HtrA4 profoundly altered a range of endo-
thelial genes related to inﬂammation, vaso-activity, angiogenesis,
cell adhesion, platelet activation and coagulation. HtrA4 also
signiﬁcantly increased HUVEC release of pro-inﬂammatory cyto-
kine IL6.
Several studies reported that maternal serum IL6 is signiﬁcantly
increased in PE patients [27]. One study in particular demonstrated
that serum IL6 was much higher in women with early-onset PE
compared to late-onset PE or normotensive controls [28]. The same
study also showed that placental IL6 expressionwas much lower in
early-onset PE, and suggested that the increase in serum IL6 was
more likely resulted from maternal endothelial dysfunction than a
direct consequences of defective placenta [28]. Our current study
provides strong support for this view. Furthermore, HtrA4 also
signiﬁcantly up-regulated two other major pro-inﬂammatory
genes, PTGS2 (COX2) and IL1B, further suggesting that the circu-
lating HtrA4 of placenta-origin can intensify the inﬂammatory
response of maternal endothelial cells, which is frequently
observed in early-onset PE [29e31].
Additional inﬂammatory factors such as TNF-a are reported to
be signiﬁcantly elevated in preeclamptic serum [9,32], it is likely
that many of these factors are released directly by the placenta.Endothelial cells are always considered to be the major site of in-
ﬂammatory response in PE, this study supports this view and
suggests that maternal endothelial cells also release multiple in-
ﬂammatory factors to the circulation as a response to placental
factors such as HtrA4.
The only down-regulated gene identiﬁed in the inﬂammation
category was CCL2, which encodes for MCP-1. The main function of
this protein is to recruit monocytes or macrophages to the site of
inﬂammation as a result of tissue injury or infection [33,34]. MCP1
is involved in many human diseases, and is expressed in many cell
types including the endothelial cells [33]. MCP1 is reported to be
higher in PE women [35], however, the majority of these reports
relate to placental production of MCP1, which acts locally to recruit
macrophages from the blood stream across the endothelium
[36,37]. In particular, MCP1 secretion is reported to be elevated in
placental mesenchymal stromal cells isolated from PE patients [38].
However, the regulation of MCP1 expression in endothelial cells
and its role in PE has not been investigated. Our data showed a
signiﬁcant reduction of endothelial MCP1 (both mRNA and protein)
by HtrA4, this may have important implications in the effectiveness
of endothelial cells to recruit macrophages.
Our data also showed that HtrA4 affected several regulatory
factors of endothelial cell biology. For Instance, THBD, an endo-
thelial cell-speciﬁc membrane-bound receptor that functions as an
anticoagulant, was highly up-regulated by HtrA4. This is consistent
with other studies showing that serum THBD is increased in PE
Y. Wang, G. Nie / Placenta 47 (2016) 46e5554women compared to normal controls [39,40], and that THBD is a
potential marker of endothelial dysfunction to predict PE [39].
Furthermore, increased levels of THBD in the maternal circulation
negatively correlate to infant birth weight, and the highest plasma
THBD level was detected in PE pregnancy with intrauterine growth
restriction, which is often associated with early-onset PE. It was
suggested that the damage to endothelium as a result of THBD
dysregulation could have amajor impact on fetal development [41].
SERPINE1, another gene up-regulated by HtrA4, encodes the
inhibitor for ﬁbrinolysis and is also elevated in the circulation of PE
women [42]. Dysregulation of SERPINE1 protein is reported to
inhibit ﬁbrin degradation, leading to ﬁbrosis and formation of
blood clot in the blood vessel [43]. THBS1, which is reported to be
lower in women with severe PE [44], was signiﬁcantly down-
regulated by HtrA4. THBS1 is involved in many regulatory pro-
cesses of endothelial cell function such as adhesion, motility and
proliferation, and THBS1 down-regulation can signiﬁcantly impair
the normal cellular function of endothelial cells [44].
Surprisingly, only a small number of genes in the angiogenic and
vasoactive group were found to be regulated by HtrA4. This suggest
that endothelial genes in this groupmay not be the major targets of
HtrA4 action, and other placental-derived factors may be respon-
sible for their dysregulation and contribute to the endothelial
dysfunction.
Overall, our study suggests that high levels of placental-derived
HtrA4 that is circulating in early-onset PE women is a potential
causal factor of endothelial dysfunction. HtrA4 profoundly altered
HUVEC expression of several factors essential for normal endo-
thelial cell function and inﬂammation responses. As endothelial
dysfunction is a major aspect of early-onset PE development, our
study provides new insight into the underlying causes of this
disease.
One limitation of this study is that HUVEC was used as a model.
HUVEC is a well characterized cell line and commonly used for
studying endothelial biology, but it may not reﬂect all the features
of human vascular endothelial cells. Future studies will conﬁrm the
impact of HtrA4 on endothelial cells using other cell models.
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